Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Brain Metastases
Interventions: DRUG: Pembrolizumab|DRUG: Liposomal Irinotecan
Sponsor: Washington University School of Medicine
Collaborators: Merck Sharp & Dohme LLC|Ipsen